|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.18 - 4.25|
|52 Week Range||4.18 - 4.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
How far off is Avid Bioservices Inc (NASDAQ:CDMO) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
On a per-share basis, the Tustin, California-based company said it had a loss of 28 cents. Losses, adjusted to account for discontinued operations, came to 23 cents per share. The pharmaceutical posted ...
In this article, I’m going to take a look at Avid Bioservices Inc’s (NASDAQ:CDMO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
When Avid Bioservices Inc (NASDAQ:CDMO) released its most recent earnings update (31 October 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
Peregrine Pharmaceuticals (PPHM) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and year.
Stock Monitor: Peregrine Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Mesoblast Ltd (NASDAQ: MESO ), which is readily accessible ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Peregrine Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to PPHM-US. Comparing the performance and risk of Peregrine Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Peregrine Pharmaceuticals, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Peregrine Pharmaceuticals, Inc. – Merck & Co., Inc., Madrigal Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Fennec Pharmaceuticals Inc. and Celldex Therapeutics, Inc. (MRK-US, ... Read more (Read more...)
The Tustin, California-based company said it had a loss of 31 cents per share. Losses, adjusted for restructuring costs, came to 27 cents per share. The pharmaceutical posted revenue of $12.8 million in ...
NEW YORK, NY / ACCESSWIRE / December 11, 2017 / Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) will be discussing their earnings results in their Q2 Earnings Call to be held on December 11, 2017 at 4:30 ...